Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

T-cell Bispecific Antibodies (TCBs) elicit anti-tumor responses by cross-linking T-cells to tumor cells and mediate polyclonal T-cell expansion that is independent of T-cell receptor specificity. TCBs thus offer great promise for patients who lack antigen-specific T-cells or have non-inflamed tumors...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Oncol
Главные авторы: Sam, Johannes, Colombetti, Sara, Fauti, Tanja, Roller, Andreas, Biehl, Marlene, Fahrni, Linda, Nicolini, Valeria, Perro, Mario, Nayak, Tapan, Bommer, Esther, Schoenle, Anne, Karagianni, Maria, Le Clech, Marine, Steinhoff, Nathalie, Klein, Christian, Umaña, Pablo, Bacac, Marina
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2020
Предметы:
Oncology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735156/
https://ncbi.nlm.nih.gov/pubmed/33330050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.575737
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы